Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean Frederic Colombel

Showing results (261-270 of 377) with videos related to

Pageof 38
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2022
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentEdward V Loftus, Jean-Frederic Colombel, Ken Takeuchi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled TrialsJennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
Pageof 38

Showing results (261-270 of 377) with videos related to

Sort By:
Pageof 38
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2022
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentEdward V Loftus, Jean-Frederic Colombel, Ken Takeuchi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled TrialsJennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
Pageof 38